Buprenorphine HCl 8 mg Sublingual Tablet
RxNorm 351265
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 351265 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: buprenorphine HCl 8 mg Sublingual Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Buprenorphine 8 mg Sublingual Tablet
(Atom ID: 12326027)
PTPrescribable
Designated preferred name (PT):
Buprenorphine (as buprenorphine hydrochloride) 8 mg sublingual tablet
(Atom ID: 10295215)
SYPrescribable
Synonym (SY):
Buprenorphine 8 mg (as buprenorphine HCl 8.64 mg) Sublingual Tablet
(Atom ID: 9703329)
PSNPrescribable
Prescribable Name (PSN):
Buprenorphine HCl 8 mg Sublingual Tablet
(Atom ID: 6821620)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 8 mg/1 each conventional release sublingual tablet (clinical drug)
(Atom ID: 10310023)
Patient Education
Buprenorphine Sublingual and Buccal (opioid dependence)
Buprenorphine and the combination of buprenorphine and naloxone are used to treat opioid dependence (addiction to opioid drugs, including heroin and narcotic painkillers). Buprenorphine is in a class of medications called opioid partial agonist-antagonists and naloxone is in a class of medications called opioid antagonists. Buprenorphine alone and the combination of buprenorphine and naloxone work to prevent withdrawal symptoms when someone stops taking opioid drugs by producing similar effects to these drugs.
[Learn More]
* Please review the disclaimer below.